scholarly journals Amelioration of liver function and glucose control with pioglitazone in a patient with diabetes mellitus type 2 and nonalcoholic fatty liver disease

2017 ◽  
Vol 5 (6) ◽  
pp. 199-202
Author(s):  
Katarzyna Nabrdalik ◽  
Patrycja Pokrzywnicka ◽  
Diana Nabrdalik-Leśniak ◽  
Jakub Gumprecht ◽  
Hanna Kwiendacz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Liver Function ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Glucose Control ◽  
Fatty Liver Disease ◽  
Diabetes Mellitus Type 2 ◽  
Nonalcoholic Fatty Liver

DIABETES MELLITUS TYPE 2 AND NONALCOHOLIC FATTY LIVER DISEASE

2011 ◽  
Vol 22 ◽  
pp. S93
Author(s):  
Maria Triantafillidou ◽  
Spiros Zidros ◽  
Athanasios Halvatzis ◽  
Nikoleta Malliarou ◽  
Amalia Faltaka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
Nonalcoholic Fatty Liver

Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features

2017 ◽  
Vol 28 (1) ◽  
pp. 187-194 ◽  
Author(s):  
Everton Cazzo ◽  
Laísa Simakawa Jimenez ◽  
Martinho Antonio Gestic ◽  
Murillo Pimentel Utrini ◽  
Fábio Henrique Mendonça Chaim ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Glucose Metabolism ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals The Outcomes of an Improved Treatment of Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease

2021 ◽  
pp. 79-83
Author(s):  
Halyna Mykhalchyshyn
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Measures ◽  
Type Two Diabetes

Nowadays we notice the increase of cases that combine type two diabetes mellitus, and nonalcoholic fatty liver disease. As a result, the course of disease aggravates. The pathogenesis, diagnoses and treatment of NAFLD remain unclear. The objective: of our study is to determine the clinical efficacy of an improved therapeutic measures set in patients with type 2 diabetes and NAFLD. Materials and methods. We’ve examined 132 patients with type 2 diabetes mellitus and NAFLD. All patients gave their consent to participate in the study. They also received all necessary nutrition and workout recommendations. We split the patients into two groups. First group patients (n=37) received antihyperglycemic drugs (metformin, gliclazide or glimepiride). Patients of the second group (n=95) additionally received DPP-4 inhibitors (saxagliptin or sitagliptin), atorvastatin, and the multiprobiotic. Patients of the second group were divided into 2 subgroups: 2A group with standard level of transaminases, and 2B group with an increased level of transaminases accordingly. Results. Improved set of therapeutic measures revealed distinctively positive effect on the dynamics of clinical manifestation of lesions of the hepatobiliary system in patients with diabetes. There were no such changes in another group. Under the influence of complex treatment in the second group of patients, the functional state of liver improved due to a significant decrease of ALT, AST, TG and VLDL levels in the blood serum. Size of the liver decreased, liver stiffness indicators improved according to shear wave elastography data. Conclusions. Combined therapy, which includes DPP-4 inhibitors, statins and multiperiodic is effective in the treatment of patients with type two diabetes and nonalcoholic fatty liver disease.

Sign in / Sign up

Export Citation Format

Share Document